NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

QuidelOrtho Corporation (QDEL) Stock Analysis

QuidelOrtho Corporation (QDEL) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

QDEL

$13.97

+$0.04 (+0.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QDEL with… →

QDEL Key Statistics

As of Sep 4, 2026
Trading
Open
$13.92
Previous Close
$13.93
Day's Range
13.51–14.30
52-Week Range
9.92–35.58
Volume
890.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$958.00M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.69
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.06
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.36
EPS (ttm)Profit attributable to each share over the last twelve months.
−15.47
Financials (FY)
Revenue (FY)
$2.73B−1.89%
Net Income (FY)
−$1.13B
Profit marginThe share of revenue left as profit after all costs and taxes.
−39.20%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.58M
1-Year Return
−49.73%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QDEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−51.09%
2025−35.89%
2024−39.55%
2023−13.97%
2022−36.54%
2021−24.86%
2020+139.44%
2019+53.69%
2018+12.62%
2017+102.38%
2016 (partial year)−5.43%

As of September 4, 2026.

QDEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.73B−$1.13B−41.5%
2024$2.78B−$2.05B−73.7%
2023$3.00B−$10.10M−0.3%
2022$3.27B$548.70M16.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.73B$1.27B$54.80M−$1.13B−41.5%
2024$2.78B$1.29B$45.80M−$2.05B−73.7%
2023$3.00B$1.50B$257.00M−$10.10M−0.3%
2022$3.27B$1.94B$982.50M$548.70M16.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QDEL Valuation vs Medical Devices Median

Median of 151 stocks
MetricQDELMedical Devices medianvs median
P/S ratio0.362.980.1x the median
Profit margin−39.20%−1.69%37.5 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

QuidelOrtho Corporation (QDEL) is capitalised at $958.00M on the latest close. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 6,500.

QDEL last closed at $13.97 on September 4, 2026. That is +$0.04 (+0.29%) against the previous close. The 52-week range on file runs from $9.92 to $35.58. The latest close sits 40.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.73B. Against the prior fiscal year total of $2.78B, that is a change of −1.89%. The same year closed with a net loss of $1.13B. The reported profit margin is −39.2%. That is 37.5 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −15.47.

Across the 4 fiscal years on file, revenue moves from $3.27B in 2022 to $2.73B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 9.69. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.06. Measured against sales, the shares trade at 0.36 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −49.73%. Measured over 10 years, that is −4.26% a year compounded. The reported beta is 0.68. Daily returns over the trailing 10 years annualize to a volatility of 59.55%.

Growth & Income

The record shows no dividend for QDEL.

Across the complete calendar years on file, 2020 returned +139.44% and 2024 returned −39.55%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −51.09% year to date.

Peer Comparison

QuidelOrtho Corporation (QDEL) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
QuidelOrtho Corporation QDEL $958.00M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. QuidelOrtho Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Visit website →